Clinical Report: Identifying Immune Ecotypes Responsive to Therapy in ccRCC
Background
Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, characterized by its association with von Hippel-Lindau (VHL) gene inactivation and a unique immune microenvironment. Despite advancements in immunotherapy, including immune checkpoint inhibitors (ICIs), patient responses are heterogeneous.
Data Highlights
No numerical or trial data available in the provided source material.
Key Findings
Immune activity in ccRCC is influenced by VHL loss, HIF signaling, and metabolic adaptation.
Common biomarkers like PD-L1 expression and tumor mutation burden do not reliably predict treatment responses in ccRCC.
High CD8+ T-cell infiltration may correlate with poorer survival.
Different immune states, such as dysfunctional T-cell-inflamed tumors and myeloid-dominant suppressive tumors, affect treatment outcomes.
Multi-omics approaches are proposed to better define immune ecotypes.
Clinical Implications
Understanding the immune ecology of ccRCC can aid in identifying patients who may respond to specific immunotherapies.
Conclusion
The immune ecology framework offers a perspective for enhancing the understanding of treatment responses in ccRCC.
